Atlantic Equities analyst Steve Chesney maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $220 to $295.
Scotiabank Upgrades Softchoice to Sector Outperform, Raises Price Target to C$32
Scotiabank upgrades Softchoice (TSX:SFTC) from Sector Perform to Sector Outperform and raises the price target from C$30 to C$32.